Literature DB >> 12378619

Association of hTcf-4 gene expression and mutation with clinicopathological characteristics of hepatocellular carcinoma.

Ying Jiang1, Xin-Da Zhou, Yin-Kun Liu, Xin Wu, Xiao-Wu Huang.   

Abstract

AIM: Hepatocellular carcinoma(HCC) is a significant health problem in China. But the molecular mechanisms of HCC remains unclear. APC/beta-Catenin/Tcf signaling pathway, also known as Wnt pathway, plays a critical role in the development and oncogenesis. As little is known about the alteration of human T-cell transcription factor-4 (hTcf-4) gene in HCC, it is of interest to study the expression and mutation of hTcf-4 gene in HCC and the relationship between hTcf-4 gene and progression of HCC.
METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) method was used to detect the expression of hTcf-4 mRNA in 32 HCC and para-cancerous tissues and 5 normal liver tissues. PCR-single strand conformation polymorphism (PCR-SSCP) method was used to detect the mutation of hTcf-4 exons 1, 4, 9 and 15 in HCC. The correlation of expression and mutation of the hTcf-4 gene with clinicopathological characteristics of HCC was also analyzed.
RESULTS: RT-PCR showed that the expression rate of hTcf-4 mRNA in HCC, para-cancerous tissues and normal liver tissues was 90.6 %, 71.9 % and 80 %, respectively. The gene expression level in tumor was 0.71+/-0.13, much higher than that in para-cancerous liver 0.29+/-0.05 and normal liver 0.26+/-0.05 (P<0.001), although there was no significant difference in gene expression level between para-cancerous tissues and normal liver (P>0.05). Furthermore, hTcf-4 gene expression was closely associated with tumor capsule status and intrahepatic metastasis of HCC. On SSCP, 2 of 32 cases of HCC (6.25 %) displayed characteristic mutational mobility shifts in exon 15 of the hTcf-4 gene. No abnormal shifting bands were observed in para-cancerous tissues.
CONCLUSION: The high expression level of hTcf-4 in HCC, especially in tumors with metastasis, suggests that the over-expression of hTcf-4 gene may be closely associated with development and progression of HCC, but the mutation of this gene seemed to play less important role in this respect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378619      PMCID: PMC4656565          DOI: 10.3748/wjg.v8.i5.804

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  43 in total

1.  Polymorphisms in cyclin D1 gene and hepatocellular carcinoma.

Authors:  Yu-Jing Zhang; Shu-Yuan Chen; Chien-Jen Chen; Regina M Santella
Journal:  Mol Carcinog       Date:  2002-02       Impact factor: 4.784

Review 2.  The Yin-Yang of TCF/beta-catenin signaling.

Authors:  N Barker; P J Morin; H Clevers
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

3.  Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex.

Authors:  K Willert; S Shibamoto; R Nusse
Journal:  Genes Dev       Date:  1999-07-15       Impact factor: 11.361

4.  Beta-catenin activation through mutation is rare in rectal cancer.

Authors:  M Nilbert; E Rambech
Journal:  Cancer Genet Cytogenet       Date:  2001-07-01

5.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

6.  Bridging of beta-catenin and glycogen synthase kinase-3beta by axin and inhibition of beta-catenin-mediated transcription.

Authors:  C Sakanaka; J B Weiss; L T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

7.  Wnt signaling controls the phosphorylation status of beta-catenin.

Authors:  Mascha van Noort; Jan Meeldijk; Ruurd van der Zee; Olivier Destree; Hans Clevers
Journal:  J Biol Chem       Date:  2002-02-07       Impact factor: 5.157

8.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma.

Authors:  D L Rimm; K Caca; G Hu; F B Harrison; E R Fearon
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

9.  Identification of c-MYC as a target of the APC pathway.

Authors:  T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1998-09-04       Impact factor: 47.728

10.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.

Authors:  M Shtutman; J Zhurinsky; I Simcha; C Albanese; M D'Amico; R Pestell; A Ben-Ze'ev
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

View more
  9 in total

1.  Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China.

Authors:  Ru-Lin Cai; Wei Meng; Hong-Yan Lu; Wen-Yao Lin; Feng Jiang; Fu-Min Shen
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

2.  Dickkopfs and Wnt/β-catenin signalling in liver cancer.

Authors:  Sarwat Fatima; Nikki P Lee; John M Luk
Journal:  World J Clin Oncol       Date:  2011-08-10

3.  Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxity.

Authors:  Shao-Shan Wang; Ti Zhang; Xi-Lu Wang; Li Hong; Qing-Hui Qi
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

4.  Antisense Tcf inhibits the neoplastic growth of liver cancer cells.

Authors:  Ying Jiang; Xin-Da Zhou; Yin-Kun Liu; Xiao-Wu Huang; Yan Zhao; Qiang Xue; Rui-Xa Sun; Jie Chen; Xin Wu
Journal:  J Cancer Res Clin Oncol       Date:  2004-11       Impact factor: 4.553

5.  Replication study for the association of TCF7L2 with susceptibility to type 2 diabetes in a Japanese population.

Authors:  T Hayashi; Y Iwamoto; K Kaku; H Hirose; S Maeda
Journal:  Diabetologia       Date:  2007-03-06       Impact factor: 10.122

6.  Association of TCF7L2 Genetic Polymorphisms with Type 2 Diabetes Mellitus in the Uygur Population of China.

Authors:  Hua Yao; Zhiqiang Wang; Tingting Wang; Yan Ma; Yinxia Su; Qi Ma; Li Wang; Jun Zhu
Journal:  Int J Environ Res Public Health       Date:  2015-09-18       Impact factor: 3.390

7.  Silencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis.

Authors:  Can Liu; Siqi He; Jianfei Zhang; Shiyan Li; Jian Chen; Chaofei Han
Journal:  Onco Targets Ther       Date:  2020-05-29       Impact factor: 4.147

8.  Roles of β-catenin, TCF-4, and survivin in nasopharyngeal carcinoma: correlation with clinicopathological features and prognostic significance.

Authors:  Pei-Ying Jin; Zi-Hui Zheng; Hong-Jie Lu; Jing Yan; Gui-Hong Zheng; Yuan-Lin Zheng; Dong-Mei Wu; Jun Lu
Journal:  Cancer Cell Int       Date:  2019-02-28       Impact factor: 5.722

9.  TCF 4 tumor suppressor: a molecular target in the prognosis of sporadic colorectal cancer in humans.

Authors:  Mumtaz Anwar; Pooja Malhotra; Rakesh Kochhar; Alka Bhatia; Akhtar Mahmood; Rajinder Singh; Safrun Mahmood
Journal:  Cell Mol Biol Lett       Date:  2020-03-31       Impact factor: 5.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.